Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
25 août 2022 16h30 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
11 août 2022 07h00 HE
|
Finch Therapeutics Group, Inc.
On track to proceed with enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI in H2 2022On track to submit IND for FIN-211 in children with autism and significant GI symptoms in Q4...
Finch Therapeutics to Participate in Upcoming June Investor Conferences
02 juin 2022 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
17 mai 2022 08h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
16 mai 2022 07h00 HE
|
Finch Therapeutics Group, Inc.
FDA lifted clinical hold on IND for CP101Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022$15 million drawn from new $55 million term debt facility...
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
09 mai 2022 08h22 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND
28 avr. 2022 17h20 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs
19 avr. 2022 08h30 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
31 mars 2022 16h56 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection
01 mars 2022 16h30 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics” or “Company”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company...